Compare DexCom, Inc. (DXCM) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Mondaycom Ltd — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while Mondaycom Ltd trades at $85.48 (market cap $3.70B). The key difference: DexCom, Inc. is far larger — about 9.1× Mondaycom Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| DXCM | MNDY | |
|---|---|---|
Market Cap | $33.79B | $3.70B |
Sector | Health | Technology |
52-Week High | $89.53 | $219.15 |
52-Week Low | $54.84 | $58.81 |
Enterprise Value | $33.24B | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
Monday.com (MNDY) trades at $85.95, down 3.01% amid mixed signals. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $1.48 versus $1.11 expected, and revenue growth of 22% year-over-year. However, weak Q3 revenue guidance has triggered a sell-off. Technical indicators are neutral with support at $83 and resistance at $89. Analyst consensus remains bullish with a $113.38 price target.
Outlook is cautiously optimistic due to robust earnings beats and AI product growth, but near-term risks include slower revenue guidance and competitive pressures. The high P/E of 37.04 suggests premium valuation, demanding sustained execution. Investors should weigh strong profitability against guidance concerns for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
